Based on the above results showing that activin A is the downstream target of MT1G-NF-κB regulatory axis, we tried to assess the therapeutic potential of inhibiting activin A signaling to overcome gemcitabine resistance in MT1G downregulated pancreatic cancer. This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.